Business Wire

Suzano reports operating cash generation of R$ 3.9 billion in the first quarter of 2022

Share

Suzano, one of the world’s largest integrated pulp and paper producers, announces its first quarter results for 2022 (1Q22) with Adjusted EBITDA reaching R$ 5.1 billion, up 5% on the same period last year. Operating cash generation, another important indicator of the company's financial performance, reached R$ 3.9 billion, consistent with levels seen this time last year.

Despite first quarter headwinds from rising input costs, such as chemicals and fuels, and an appreciating Brazilian Real, the company continues to invest in its production capacity with total disbursements of R$ 13.6 billion planned for 2022.

Suzano continues to maintain healthy levels of indebtedness and leverage, measured by the ratio of net debt to adjusted EBITDA which stood at 2.4 times (USD), an improvement on 3.8 times at this point last year. Net debt was almost stable during the quarter (USD 10.5 billion), despite the growth in investments and the dividend payment in January.

Pulp sales reached 2.4 million tons, driven by a higher concentration of scheduled downtimes at Suzano's mills in 1Q22. Pulp cash costs reached R$ 868 per ton, an increase of 16% on the last quarter of 2021. The company’s pulp inventory levels remained low due to strong demand in the quarter.

Paper sales totaled 312 thousand tons. Net revenue, including pulp and paper sales, amounted to R$ 9.7 billion.

“We had a quarter of consistent cash generation, despite higher input costs and the strengthening of the Real against the Dollar. These effects were partially mitigated by higher prices in the international market, not completely reflected in the results, and by the efficiency of our business model and the competence of our team on the operational and commercial fronts. We continue to positively advance our strategic priorities as expected, with continued ESG progress and the transformational Cerrado project remaining on time and on budget,” said Walter Schalka, CEO of Suzano, referring to the construction of a pulp mill in Ribas do Rio Pardo, Mato Grosso do Sul state.

The exchange variation during the first quarter of 2022 led the company to record a positive net result of R$ 10.3 billion on the bottom line of the balance sheet.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of

Trading Central wins at the Technical Analyst Awards26.5.2022 17:30:00 CEST | Press release

The Technical Analyst Awards recognize the best in market research, financial data, software and artificial intelligence. At the 2022 edition, industry peers voted Trading Central a winner in three categories: Best AI Product, Most Innovative New Product & Best Multi-Asset Data Provider. Trading Central’s suite of embeddable apps & APIs power the world’s leading online broker platforms to support investors and active traders throughout their decision making journey. We’re proud to be recognized for our relentless efforts to challenge ourselves, innovate and disrupt the industry. TC Market Buzz® for Best AI Product Read less, know more TC Market Buzz leverages Artificial Intelligence to make sense of the millions of news headlines, social media posts and articles posted online every day. It replaces static headlines with simple, compelling and informative data visualizations. Users can: Identify what instruments are buzzing based on news volume View the most discussed topics for an inst